Skip to main content
Premium Trial:

Request an Annual Quote

Hyrax Biosciences, Roche Diagnostics Form SARS-CoV-2 Sequencing Tech Alliance

NEW YORK — South African bioinformatics firm Hyrax Biosciences said on Tuesday that it has signed an agreement to comarket its Exatype automated DNA analysis platform with Roche Diagnostics' research-use-only KAPA HyperCap SARS-CoV-2 panel.

Financial and other terms of the deal were not disclosed.

According to Hyrax, Roche's KAPA HyperCap workflow allows one-day sample preparation while the SARS-CoV-2 panel provides high specificity, uniformity, and success rates from low viral load inputs. The Exatype platform automates sequence analysis and includes SARS-CoV-2 lineage/clade typing algorithms for read mapping and variant calling.

"Pairing our Exatype analysis platform with Roche's KAPA HyperCap SARS-CoV-2 panel ensures high and uniform coverage of the viral genome, which is of the utmost importance in confident identification of emerging isolates and variants," Hyrax CEO Simon Travers said in a statement. "Combining these technologies into a single workflow will lead to higher quality results and increased reliability of sequencing-based viral genotyping."

The Scan

Panel Votes for COVID-19 Pill

A US Food and Drug Administration panel has voted to support the emergency use authorization of an antiviral pill for COVID-19 from Merck and Ridgeback Biotherapeutics, CNN says.

But Not Harm

New Scientist reports that UK bioethicists say that though gene editing may improve food production, it should not harm livestock welfare.

Effectiveness Drop Anticipated

Moderna's Stéphane Bancel predicts that that current SARS-CoV-2 vaccines may be less effective against the Omicron variant, the Financial Times reports.

Cell Studies of Human Chromatin Accessibility, SARS-CoV-2 Variants, Cell Signaling Networks

In Cell this week: chromatin accessibility maps of adult human tissues, modeling to track SARS-CoV-2 variants of concern, and more.